Newbridge Financial Services Group’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-77
Closed -$1.81K 1049
2024
Q4
$1.81K Sell
77
-14
-15% -$345 ﹤0.01% 978
2024
Q3
$2.33K Sell
91
-444
-83% -$11.3K ﹤0.01% 551
2024
Q2
$12.6K Hold
535
﹤0.01% 663
2024
Q1
$15.4K Sell
535
-114
-18% -$3.43K 0.01% 665
2023
Q4
$21.3K Buy
649
+87
+15% +$2.37K 0.01% 582
2023
Q3
$15.7K Sell
562
-251
-31% -$8.21K 0.01% 704
2023
Q2
$27.7K Sell
813
-92
-10% -$2.89K 0.01% 597
2023
Q1
$27.2K Sell
905
-457
-34% -$14.2K 0.01% 619
2022
Q4
$38.5K Hold
1,362
0.02% 527
2022
Q3
$45K Buy
1,362
+215
+19% +$7.89K 0.03% 472
2022
Q2
$36K Buy
1,147
+368
+47% +$12.9K 0.02% 480
2022
Q1
$36K Buy
779
+120
+18% +$5.72K 0.02% 557
2021
Q4
$40K Sell
659
-164
-20% -$11.3K 0.02% 523
2021
Q3
$61K Sell
823
-96
-10% -$8.05K 0.04% 357
2021
Q2
$85K Buy
919
+86
+10% +$7.31K 0.05% 313
2021
Q1
$74K Buy
833
+732
+725% +$72.6K 0.05% 311
2020
Q4
$9K Buy
+101
New +$8.05K 0.01% 748

Other funds holding ARKG

Newbridge Financial Services Group's ARKG Position: Q1 2025 in Review

Newbridge Financial Services Group sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2025, closing a stake of 77 shares — an estimated $1.81K sold.

Newbridge Financial Services Group first reported a position in ARKG in Q4 2020 and held it in 17 quarters. The position peaked at $85K in Q2 2021. 214 funds tracked by Wall St. Rank hold ARKG as of Q1 2025.

  • Newbridge Financial Services Group reported no remaining ARK Genomic Revolution ETF position as of Q1 2025 after selling out during the quarter.
  • Newbridge Financial Services Group sold 77 ARK Genomic Revolution ETF shares in Q1 2025, an estimated $1.81K.
  • Newbridge Financial Services Group first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 17 quarters.
  • Newbridge Financial Services Group's ARK Genomic Revolution ETF position peaked at $85K in Q2 2021.
  • 214 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2025.

Based on Newbridge Financial Services Group's 13F filing for Q1 2025, filed 15 May 2025.